Deregulated expression of receptor tyrosine kinases (RTKs) may have a prognostic relevance in ovarian carcinoma and activation of survival pathways downstream of RTKs is known to be involved in cellular drug resistance both to conventional drugs and to targeted agents [5,6]. This evidence concerns the gene NTRK1 and ovarian carcinoma.